Most recently, Dr. Patz’s lab developed the first human-derived antibody for the treatment of lung cancer. Using an innovative strategy that explored the response of lung cancer patients with early-stage non-small cell lung cancer (NSCLC) who never developed metastatic disease, they discovered that some patients had an antibody that blocks an essential tumor cell protective protein called complement factor H (CFH). This anti-CFH antibody caused tumor cell death through activation of a biologic cascade and adaptive immune response in patients with lung cancer.
Dr. Patz’s innovative research in now in a Phase 1 clinical trial for patients with advanced stage NSCLC. This trial is open for enrollment, and listed at ClinicalTrial.gov.
For addition information about the Patz laboratory, please visit his website.